Fenebrutinib wins head‑to‑head in MS

Roche’s experimental oral BTK inhibitor fenebrutinib beat an approved oral MS drug in a large head‑to‑head Phase III trial, and the company says the win clears the way for regulatory filings — but the dataset also contains safety flags that will shape how regulators and companies manage post‑market surveillance. (gene.com) In the pivotal FENhance 1 study, fenebrutinib reduced the annualized relapse rate by 51% versus teriflunomide (Aubagio) over at least 96 weeks in people with relapsing MS. (roche.com) This is the second RMS study with a large effect: FENhance 2 had previously shown a 59% reduction versus the same active comparator. (roche.com) Fenebrutinib works by blocking Bruton’s tyrosine kinase (BTK), a signaling enzyme inside certain immune cells. Blocking BTK dials down damaging B‑cell activity in the periphery and appears to alter microglial activity inside the brain — Roche calls the molecule “brain‑penetrant,” which is why an oral pill can show effects on both relapses and imaging markers of CNS inflammation. (neurologylive.com) Roche is positioning the three‑trial program — two RMS trials and a PPMS trial — as the package it will submit to regulators; full Phase III datasets are slated for presentation at the American Academy of Neurology annual meeting in 2026 and then for regulatory review. (gene.com) Safety is where the regulatory choreography will get intensive. In the combined FENhance 1 and 2 programs Roche reported eight fatal cases in the fenebrutinib arms versus one in the teriflunomide arm, and noted liver transaminase elevations that were comparable between arms; company statements say further analyses are underway. (roche.com) For a patient‑safety leader this pattern matters for three concrete reasons. First, superiority against an active comparator strengthens the case for approval but also raises expectations that the sponsor will deliver robust comparative safety data in the dossier and post‑market. FDA and EMA frameworks already require explicit risk‑management planning and can attach postmarketing studies or REMS to approvals; sponsors should assume regulators will look for rapid, prospective safety follow‑up if fatal events cluster or cannot be readily explained. (fda.gov) (ema.europa.eu) Second, the nature of the events will drive surveillance design. If liver enzyme elevations are confirmed signals, regulators will expect detailed hepatic monitoring plans, stopping rules, and clear labeling language. If fatal events lack an obvious pattern, regulators may require broad post‑authorization observational studies and mortality adjudication committees to detect rare but serious risks. (roche.com) Third, comparative trials change the way pharmacovigilance messaging is read by clinicians and payers. An oral therapy that claims both high efficacy and CNS penetration will be scrutinized for chronic risks (infections, bleeding, hepatic injury) that BTK inhibition can carry, and health authorities increasingly demand tailored RMPs and registries to track those endpoints. (ema.europa.eu) Roche’s next regulatory steps are concrete: present full data at AAN 2026, submit the combined Phase III package to agencies, and continue safety analyses already in progress. Those documents will determine whether regulators approve fenebrutinib with routine safety monitoring, impose specific post‑marketing studies, or require other risk‑minimization measures. (gene.com)